Ruxolitinib, a Janus kinase 1/2 (JAK1/2) inhibitor, has been shown to be effective in some forms of secondary HLH both as monotherapy and in combination with doxorubicin, etoposide and dexamethasone [39,40]. This evidence concerns the gene JAK1 and hemophagocytic syndrome.